XCUR vs. NRSN, FLGC, TRAW, EDSA, RDHL, AKTX, IMNN, PIRS, KPRX, and ELAB
Should you be buying Exicure stock or one of its competitors? The main competitors of Exicure include NeuroSense Therapeutics (NRSN), Flora Growth (FLGC), Traws Pharma (TRAW), Edesa Biotech (EDSA), RedHill Biopharma (RDHL), Akari Therapeutics (AKTX), Imunon (IMNN), Pieris Pharmaceuticals (PIRS), Kiora Pharmaceuticals (KPRX), and Elevai Labs (ELAB). These companies are all part of the "pharmaceutical preparations" industry.
NeuroSense Therapeutics (NASDAQ:NRSN) and Exicure (NASDAQ:XCUR) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk, media sentiment, earnings and community ranking.
NeuroSense Therapeutics has a beta of 1.73, meaning that its stock price is 73% more volatile than the S&P 500. Comparatively, Exicure has a beta of 1.31, meaning that its stock price is 31% more volatile than the S&P 500.
In the previous week, NeuroSense Therapeutics had 1 more articles in the media than Exicure. MarketBeat recorded 3 mentions for NeuroSense Therapeutics and 2 mentions for Exicure. NeuroSense Therapeutics' average media sentiment score of 1.09 beat Exicure's score of 0.62 indicating that Exicure is being referred to more favorably in the news media.
Exicure has higher revenue and earnings than NeuroSense Therapeutics. NeuroSense Therapeutics is trading at a lower price-to-earnings ratio than Exicure, indicating that it is currently the more affordable of the two stocks.
1.0% of NeuroSense Therapeutics shares are owned by institutional investors. Comparatively, 42.8% of Exicure shares are owned by institutional investors. 27.4% of NeuroSense Therapeutics shares are owned by company insiders. Comparatively, 3.9% of Exicure shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
NeuroSense Therapeutics' return on equity of 27.15% beat Exicure's return on equity.
Exicure received 7 more outperform votes than NeuroSense Therapeutics when rated by MarketBeat users. However, 100.00% of users gave NeuroSense Therapeutics an outperform vote while only 47.37% of users gave Exicure an outperform vote.
Summary
Exicure beats NeuroSense Therapeutics on 9 of the 14 factors compared between the two stocks.
Get Exicure News Delivered to You Automatically
Sign up to receive the latest news and ratings for XCUR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding XCUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
